Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

The biotechnology firm detailed key advances across its ongoing clinical programs evaluating the oral IRAK4 and FLT3 inhibitor for targeted blood cancers. Analyst Adds CLL Valuation, Revises Launch Timelines HC Wainwright wrote that TakeAim CLL enrollment is running ahead of plan, with consented patients rising to 10 and year-end guidance raised to 5-10 patients. The analyst views the December readout as the nearest-term value driver. The firm reiterated the Buy rating on the stock and raised the price forecast from $17 to $43. Analyst Sara Nik said the update adds a valuation for emavusertib in Chronic lymphocytic leukemia (CLL) following the launch of the TakeAim CLL study, assuming a 10% probability of success, $500 million in peak sales and a 2032 commercial launch. The update also pushes the est...